INVOLVEMENT OF THE GASTROINTESTINAL TRACT IN RHEUMATIC DISEASES

The aim of the present study was to show different aspects of the interrelation between pathology of the gastrointestinal tract and rheumatic diseases based on literature rewiev, single-centers data and case reports. Materials and methods. First literature review was performed (databases PubMed, Medline). Then was analyzed information according presence of gastrointestinal disease in 126 patients with axial spondyloarthritis (SpA) and collected case reports as illustration the problem. Results. Involvement of the gastrointestinal tract in rheumatic diseases in general is characterized by clinical, etiologycal and pathogenetic heterogeneity. It was found a few typical combinations: the defeat of the digestive tract as one of the clinical manifestations of rheumatic disease (hemorrhagic vasculitis, etc.); the defeat of the digestive tract and rheumatic disease as equal related conditions (Crohn’s disease and ankylosing spondylitis); the defeat of the digestive tract as a consequence of long-existing inflammation (amyloidosis, esophagus Barrett); gastrointestinal tract involvement as complication of treatment of the rheumatic disease (bleeding when using nonsteroidal anti-inflammatory drugs); rheumatic disease as a manifestation of paraneoplastic syndrome of the digestive tract. The presence of diseases of the gastrointestinal tract is established in more than half (58%) patients with axial SpA. In the group of patients considered the most frequently met gastritis (15%), chronic pancreatitis (15.9%) and chronic cholecystitis (19%). Conclusions. Gastrointestinal tract occurs no less than half of the patients with rheumatic diseases and may be either primary or secondary to systemic disease. The possibility of coexistence of diseases of the gastrointestinal tract and rheumatic disease must be taken into account in the course of patient care. In some cases, treatment should be carried out together - a gastroenterologist and a rheumatologist.

comorbidity, pathology of the gastrointestinal tract, rheumatic diseases, spondylitis, NSAID-gastropathy, gastrointestinal bleeding, ulcerative colitis, amyloidosis

1. Solomon D. H., Peters M. J., Nurmohamed M. T., Dixon W. Motion for debate: the data support evidence-based management recommendations for cardiovascular diseases in rheumatoid arthritis // Arthritis Rheum. - 2013. - 66 (7). - P. 1675-83. DOI: 10.1002/art. 37 975.

2. Marigliano B., Soriano A., Margiotta D., et al. Lung involvement in connective tissue diseases: a comprehensive review and a focus on rheumatoid arthritis / Autoimmunity Rev. - 2013. - 12 (11). - P. 1076-84. DOI: http://dx.doi.org/10.1016/j. autrev. 2013.05.001.

3. Anders H. J., Vielhauer V. Renal co-morbidity in patients with rheumatic diseases / Arthritis Res Ther. - 2011. - 13 (3). - P. 222-32. DOI: http://dx.doi.org/10.1186/ar3256.

4. Turesson E. L., Matteson E. L. Malignancy as a comorbidity in rheumatic diseases / Rheumatology (Oxford). - 2013. - 52 (1). - P. 5-14. DOI: http://dx.doi.org/10.1093/rheumatology/kes189.

5. Панафидина Т. А., Кондратьева Л. В., Герасимова Е. В. и соавт. Коморбидность при ревматоидном артрите / Научно- практическая ревматология. - 2014. - 52 (3). - С. 283-9. [Panafidina TA, Kondrat’eva LV, Gerasimova EV, et al. Comorbidity in rheumatoid arthritis / Nauchno-prakticheskaya revmatologiya = Rheumatology Science and Practiсе. - 2014. - 52 (3). - P. 283-9. (In Russ.)]. DOI: http://dx.doi.org/10.14 412/1995-4484-2014-283-289.

6. Dougados, M., et al., Prevalence of comorbidities in rheumatoid arthritis and evaluation of their monitoring: results of an international, cross-sectional study (COMORA). Ann Rheum Dis, 2014. 73 (1): p. 62-8.

7. Насонов Е. Л. Сегодня в изучении патогенеза ревматических болезней на первый план выходят исследования механизмов хронического воспаления // Фарматека. - 2005. - 7. - С. 4-7.

8. Papadakis K. A., Targan S. R. Role of cytokines in the pathogenesis of inflammatory bowel disease // Ann. Rev. Med. - 2000. - V. 51. - P. 289-298.

9. Targan S. R. Biology of inflammation in Crohn’s disease: mechanism of action of anti- TNF - a therapy. // Scand. J. Gastroenterol. - 2000. - v. 14. - (Suppl. C). - 13 c.

10. Rudwaleit M., van der Heijde D., Landewe R., et al. The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (Part II): validation and final selection / Ann Rheum Dis. - 2009. - 68. - P. 777-83. DOI: http://dx.doi.org/10.1136/ard. 2009.108 233.

11. Marie I. Gastrointestinal involvement in systemic sclerosis // Presse Med. - 2006. - 35 (12, Pt 2). - P. 1952-65.

12. Vander Cruyssen B., Ribbens C., Boonen A., et al. The epidemiology of ankylosing spondylitis and the commencement of anti-tnf therapy in daily rheumatology practice // Ann Rheum Dis. - 2007. - 66 (8). - P. 1072-7.

13. Song I. H., Appel H., Haibel H., et al. New onset of Crohn’s disease during treatment of active ankylosing spondylitis with etanercept. // J Rheumatol. - 2008. - 35 (3). - Р. 532-6.

14. Turina M. C., Sieper J., Yeremenko N., et al. Calprotectin serum level is an independent marker for radiographic spinal progression in axial spondyloarthritis // Ann Rheum Dis. - 2014. - 73 (9). - P. 1746-8.

15. Turina M. C., Yeremenko N, Paramarta J. E., et al. Calprotectin (S100A8/9) as serum biomarker for clinical response in proof-of-concept trials in axial and peripheral spondyloarthritis // Arthritis Res Ther. - 2014. - 16 (4). - P. 413.

16. Braun J., van den Berg R., Baraliakos X., et al. 2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis // Ann Rheum Dis. - 2011. - 70 (6). - P. 896-904. doi: 10.1136/ard. 2011.151 027. PubMed PMID: 21 540 199; PubMed Central PMCID: PMC3 086 052.

17. Lane T., et al., Therapeutic blockade of interleukin-6 by tocilizumab in the management of AA amyloidosis and systemic autoinflammatory disorders: a case series and review of the literature // Clin Exp Rheumatol. - 2015.

18. Hamanoue S., et al., Successful treatment with humanized anti-interleukin-6 receptor antibody (tocilizumab) in a case of AA amyloidosis complicated by familial Mediterranean fever // Mod Rheumatol. - 2015. - Р. 1-4.

19. Yilmaz S., et al., Tocilizumab in the treatment of patients with AA amyloidosis secondary to familial Mediterranean fever // Rheumatology (Oxford). - 2015. - 54 (3). - Р. 564-5.

20. Baker J. F., et al., Weight Loss, the Obesity Paradox, and the Risk of Death in Rheumatoid Arthritis // Arthritis Rheumatol. - 2015. - 67 (7). - Р. 1711-7.

21. Каратеев А. Е., Насонов Е. Л., Яхно Н. Н. и соавт. Клинические рекомендации «Рациональное применение нестероидных противовоспалительных препаратов (НПВП) в клинической практике» // Современная ревматология. - 2015. - 1. - С. 4-23.

22. Каратеев А. Е., Попкова Т. В., Новикова Д. С. и соавт. Оценка риска желудочно-кишечных и сердечно - сосудистых осложнений, ассоциированных с приемом нестероидных противовоспалительных препаратов в популяции СНГ: предварительные данные эпидемиологического исследования КОРОНА-2 // Научно-практическая ревматология. - 2014. - 52 (6). - С. 600-606.

23. Каратеев А. Е., Яхно Н. Н., Лазебник Л. Б. и соавт. Применение нестероидных противовоспалительных препаратов. Клинические рекомендации // под ред. А. Е. Каратеева. - Москва: ИМА-пресс, 2009. - 167 с.

24. Garcia Rodriguez L. A., Jick H. Risk of upper gastrointestinal bleeding and perforation associated with individual non-steroidal anti-inflammatory drugs // Lancet. - 1994. - 343 (8900). - P. 769-772.

25. Hansen J. M., Hallas J., Lauritsen J. M., Bytzer P. Non-steroidal anti-inflammatory drugs and ulcer complications: a risk factor analysis for clinical decision-making // Scand J Gastroenterol. - 1996. - 31 (2) - P. 126-130.

26. McCarthy D. Nonsteroidal anti-inflammatory drug-related gastrointestinal toxicity: definitions and epidemiology // Am J Med. - 1998. - 105 (5A). - P. 3S-9S.

27. Светлова М. С. Ревматические паранеопластические синдромы // Русский медицинский журнал. - 2014. - Т. 22. - № 7. - С. 496-498.

28. Chambers S., Isenberg D. Malignancy and Rheumatic Disease. A Real Association? // The Journal of Rheumatology. - 2005. - 10. - Р. 56-64.